Literature DB >> 17765378

Yi-gan san for the treatment of borderline personality disorder: an open-label study.

Tsuyshi Miyaoka1, Motohide Furuya, Hideaki Yasuda, Maiko Hayashia, Takuji Inagaki, Jun Horiguchi.   

Abstract

BACKGROUND: Numerous medications have been tested on patients with borderline personality disorder (BPD). Although many of these medications have been demonstrated to be useful, no clear main treatment for BPD has emerged. Despite the efficacy of some of the medicines, acceptability and side effects have proven to be barriers to their use. Recent studies indicate that the traditional Chinese herbal medicine yi-gan san (YGS, yokukan-san in Japanese) may be safe and useful in treating behavioral and psychological symptoms in dementia patients. We aimed at evaluating both efficacy and safety of yi-gan san in patients with well-defined BPD.
METHODS: Twenty female outpatients diagnosed with BPD according to DSM-IV criteria and the revised Diagnostic Interview for Borderlines completed a 12-week open-label study with yi-gan san at an average daily dosage of 6.4+/-1.9 g (2.5-7.5 g). Psychometric instruments to assess efficacy included the Brief Psychiatric Rating Scale (BPRS), Hamilton Rating Scales for Depression (HAM-D), Global Assessment of Functioning (GAF), Clinical Global Impression Scale (CGI), and Aggression Questionnaire (AQ).
RESULTS: Most psychometric scale scores exhibited a highly significant improvement (total BPRS; BPRS somatic concern, anxiety, tension, depressive mood, hostility, suspiciousness, motor retardation, uncooperativeness, and excitement subscale; CGI; GAF; AQ) over time.
CONCLUSIONS: In this open-label pilot study, patients treated with YGS showed statistically significant reduction on self-rated and clinician-rated scales. The present findings suggest that yi-gan san might be effective for the treatment of a number of BPD symptoms, including low mood, impulsivity, and aggression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17765378     DOI: 10.1016/j.pnpbp.2007.07.026

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  16 in total

Review 1.  State of the art in the pharmacologic treatment of borderline personality disorder.

Authors:  Louis Feurino; Kenneth R Silk
Journal:  Curr Psychiatry Rep       Date:  2011-02       Impact factor: 5.285

2.  Mother/offspring co-administration of the traditional herbal remedy yokukansan during the nursing period influences grooming and cerebellar serotonin levels in a rat model of neurodevelopmental disorders.

Authors:  Katsumasa Muneoka; Makiko Kuwagata; Tetsuo Ogawa; Seiji Shioda
Journal:  Cerebellum       Date:  2015-04       Impact factor: 3.847

3.  Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).

Authors:  Tsuyoshi Miyaoka; Motohide Furuya; Jun Horiguchi; Rei Wake; Sadayuki Hashioka; Masaya Tohyama; Norio Mori; Yoshio Minabe; Masaomi Iyo; Shyuichi Ueno; Sachiko Ezoe; Kenta Murotani; Syuzo Hoshino; Haruo Seno
Journal:  Psychopharmacology (Berl)       Date:  2014-06-13       Impact factor: 4.530

Review 4.  Diagnosis of borderline personality disorder in China: current status and future directions.

Authors:  Jie Zhong; Freedom Leung
Journal:  Curr Psychiatry Rep       Date:  2009-02       Impact factor: 5.285

5.  Geissoschizine methyl ether, an alkaloid from the Uncaria hook, improves remyelination after cuprizone-induced demyelination in medial prefrontal cortex of adult mice.

Authors:  Shoko Morita; Kouko Tatsumi; Manabu Makinodan; Hiroaki Okuda; Toshifumi Kishimoto; Akio Wanaka
Journal:  Neurochem Res       Date:  2013-11-06       Impact factor: 3.996

6.  Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, multicenter, double-blind, placebo-controlled trial.

Authors:  Tsuyoshi Miyaoka; Motohide Furuya; Jun Horiguchi; Rei Wake; Sadayuki Hashioka; Masaya Thoyama; Kenta Murotani; Norio Mori; Yoshio Minabe; Masaomi Iyo; Shuichi Ueno; Sachiko Ezoe; Syuzo Hoshino; Haruo Seno
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-14       Impact factor: 2.629

7.  Yokukansan improves distress of medical staff, and cognitive function and motivation in patients with destructive and aggressive behaviors after traumatic brain injury.

Authors:  Tomomichi Kan'o; Jing-Yan Han; Kuniaki Nakahara; Shingo Konno; Mayuko Shibata; Takao Kitahara; Kazui Soma
Journal:  Acute Med Surg       Date:  2014-03-05

8.  Yi-gan san restores behavioral alterations and a decrease of brain glutathione level in a mouse model of schizophrenia.

Authors:  Manabu Makinodan; Takahira Yamauchi; Kouko Tatsumi; Hiroaki Okuda; Yoshinobu Noriyama; Miyuki Sadamatsu; Toshifumi Kishimoto; Akio Wanaka
Journal:  J Brain Dis       Date:  2009-02-12

9.  Orengedoku-to augmentation in cases showing partial response to yokukan-san treatment: a case report and literature review of the evidence for use of these Kampo herbal formulae.

Authors:  Hideki Okamoto; Atsushi Chino; Yoshiro Hirasaki; Keigo Ueda; Masaomi Iyo; Takao Namiki
Journal:  Neuropsychiatr Dis Treat       Date:  2013-01-18       Impact factor: 2.570

10.  Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study.

Authors:  Tsuyoshi Miyaoka; Rei Wake; Motohide Furuya; Kristian Liaury; Masa Ieda; Kazunori Kawakami; Keiko Tsuchie; Takuji Inagaki; Jun Horiguchi
Journal:  BMC Psychiatry       Date:  2012-11-29       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.